在其他近期新闻中，Tiziana Life Sciences在开发免疫疗法方面取得了重大进展。公司的鼻内抗CD3单克隆抗体foralumab在减轻GLP-1激动剂（常用于代谢紊乱治疗）的副作用方面显示出潜力。Tiziana的疗法旨在抵消这些激动剂的副作用，可能改善患者的长期预后。

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...

Dr. Saef Izzy, Associate Professor of Neurology at Harvard Medical School, commented, “Treatment with nasal anti-CD3 not only dampened microglial activation but also led to marked improvements in ...

NEW YORK - Tiziana Life Sciences Ltd. (NASDAQ:TLSA), a biotech firm focused on immunomodulation therapies with a market ...

Shares of Tiziana Life Sciences rose after the company said it received positive results from its nasal anti-CD3 monoclonal antibody in traumatic spinal cord injury. The stock was up 5.3% to 84 cents ...

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...

New York-based biotech Tiziana Life Sciences today announces its intention not to engage in a capital raising activities for the immediate future.

Tiziana的新任首席执行官Ivor Elrifi正在领导鼻内foralumab的持续临床试验。Tiziana获得了340万美元的非稀释性资金，用于推进其鼻内foralumab治疗na-SPMS的2期临床试验。公司还扩大了其MS治疗的2期试验，FDA批准增加20名患者。

Tiziana Life Sciences (TLSA) announced the discovery of new immune biomarkers in patients with non-active secondary progressive multiple ...

Tiziana Life Sciences is developing foralumab, an anti-CD3 monoclonal antibody, for treating neurodegenerative diseases like SPMS and Alzheimer's, with promising early results. Positive Phase 2 ...

Tiziana Life Sciences, Ltd. has announced the publication of a review article in Nature Reviews Neurology, which highlights the potential of its lead drug candidate, intranasal foralumab ...

Tiziana Life Sciences (TLSA) announced that a review article titled “Immune mechanisms and shared immune targets in neurodegenerative diseases” was published in Nature Reviews Neurology ...